MCID: MCR004
MIFTS: 53

Macroglobulinemia

Categories: Metabolic diseases

Aliases & Classifications for Macroglobulinemia

MalaCards integrated aliases for Macroglobulinemia:

Name: Macroglobulinemia 12 76 15
Waldenstrom Macroglobulinemia 73
Primary Macroglobulinemia 12

Classifications:



Summaries for Macroglobulinemia

MalaCards based summary : Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. An important gene associated with Macroglobulinemia is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs rituximab and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is... more...

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 waldenstrom macroglobulinemia 33.9 CD40LG CXCR4 MYD88 PAX5
2 lymphoplasmacytic lymphoma 32.1 CD40LG CXCL12 CXCR4 MYD88 PAX5
3 b-cell lymphomas 30.4 BTK PAX5 TNFSF13B
4 heavy chain disease 30.4 CD40LG MYD88
5 cryoglobulinemia 30.0 CD27 CD40LG TNFSF13B
6 whim syndrome 29.8 CXCL12 CXCR4
7 agammaglobulinemia 29.7 BTK CD40LG CXCL12
8 mantle cell lymphoma 29.4 AKT1 BTK CD40LG PAX5
9 hematologic cancer 28.9 CD40LG CXCL12 CXCR4 PAX5
10 myeloma, multiple 28.8 AKT1 CD40LG CXCL12 CXCR4 IL6 TNFSF13B
11 autoimmune disease 28.3 CD40LG IL6 TNFRSF13B TNFSF13B
12 leukemia, chronic lymphocytic 27.3 CD27 CD40LG CD70 CXCL12 CXCR4 PAX5
13 lymphoma, non-hodgkin, familial 26.3 CD27 CD40LG CXCL12 CXCR4 PAX5 TNFRSF13B
14 macroglobulinemia, waldenstrom 1 12.2
15 waldenstroem's macroglobulinemia 12.0
16 macroglobulinemia, waldenstrom 2 12.0
17 schnitzler syndrome 11.4
18 monoclonal gammopathy of uncertain significance 11.3
19 light chain deposition disease 11.2
20 immunoglobulin a deficiency 1 10.7 BTK CD40LG
21 immunodeficiency with hyper-igm, type 4 10.7 CD40LG TNFSF13B
22 congenital hypogammaglobulinemia 10.7 BTK CD40LG
23 polyclonal hypergammaglobulinemia 10.7 CD40LG IL6
24 immunodeficiency with hyper-igm, type 1 10.6 BTK CD40LG
25 ascaris lumbricoides infection 10.6 IL6 TNFSF13B
26 transient arthritis 10.5 CD40LG IL6
27 central nervous system vasculitis 10.5 CD40LG IL6
28 osteosclerotic myeloma 10.5 CD40LG IL6
29 lymphoma 10.5
30 intussusception 10.5 CD40LG IL6
31 salivary gland disease 10.4 CD40LG TNFSF13B
32 toxoplasmosis 10.4 CD40LG IL6 MYD88
33 aids dementia complex 10.4 CXCL12 CXCR4
34 viral infectious disease 10.4 CD40LG CXCR4 IL6
35 hypersensitivity reaction disease 10.3 CD40LG IL6 TNFSF13B
36 immune system disease 10.3 CD40LG IL6 TNFSF13B
37 non-secretory myeloma 10.3 CD40LG ITGAE
38 hypersensitivity reaction type iii disease 10.3 CD40LG IL6
39 primary effusion lymphoma 10.3 AKT1 IL6
40 multicentric castleman disease 10.3 IL6 PAX5
41 connective tissue disease 10.3 CD40LG IL6 TNFSF13B
42 gamma heavy chain disease 10.2 CD40LG MYD88
43 plasma protein metabolism disease 10.2 BTK CD40LG CXCR4 MYD88
44 leukemia 10.2
45 primary central nervous system lymphoma 10.1 CXCL12 MYD88 PAX5
46 amyloidosis 10.1
47 intraocular lymphoma 10.1 CXCL12 CXCR4 PAX5
48 lymph node disease 10.1 CD40LG IL6 ITGAE
49 monoclonal paraproteinemia 10.1 CD27 CD40LG MYD88
50 neuropathy 10.0

Graphical network of the top 20 diseases related to Macroglobulinemia:



Diseases related to Macroglobulinemia

Symptoms & Phenotypes for Macroglobulinemia

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 MYD88 AKT1 CD40LG CD70 CXCR4
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 MYD88 AKT1 BTK CD27 CD40LG CD70

MGI Mouse Phenotypes related to Macroglobulinemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 PAX5 TNFRSF13B TNFSF13B AKT1 BTK CD27
2 cellular MP:0005384 9.91 CXCR4 IL6 MYD88 PAX5 AKT1 BTK
3 immune system MP:0005387 9.77 AKT1 BTK CD27 CD40LG CD70 CXCL12
4 neoplasm MP:0002006 9.17 AKT1 BTK CXCR4 IL6 MYD88 PAX5

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
3
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
4
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
5
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 147-94-4 6253
6
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
9
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 50-24-8 5755
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 83-43-2 6741
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
13
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
15 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
18
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antibodies Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Immunoglobulins Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
41 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Prednisolone acetate Phase 4,Phase 2,Phase 1,Not Applicable
47 Methylprednisolone acetate Phase 4,Phase 2,Phase 1,Not Applicable
48 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 1,Not Applicable
49 Neuroprotective Agents Phase 4,Phase 2,Phase 1,Not Applicable
50 Angiogenesis Inhibitors Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 476)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo Completed NCT01461928 Phase 3 Chemotherapy (Induction Period);Rituximab
12 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
13 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
14 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
15 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
18 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
22 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
25 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
26 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
27 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
28 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
29 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
30 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
31 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
32 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
33 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
36 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
37 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
38 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
39 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
40 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
41 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
42 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
43 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
44 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
45 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
46 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid
47 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
48 Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
49 Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia Completed NCT02092909 Phase 1, Phase 2 IMO-8400
50 Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00777738 Phase 2 BORTEZOMIB

Search NIH Clinical Center for Macroglobulinemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Macroglobulinemia

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

41
B Cells, Bone, Bone Marrow, Liver, T Cells, Kidney, Spleen

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

(show top 50) (show all 858)
# Title Authors Year
1
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with WaldenstrAPm macroglobulinemia. ( 29869556 )
2018
2
Idelalisib in a patient with refractory WaldenstrAPm's macroglobulinemia complicated by anuric renal failure: a case report. ( 29890999 )
2018
3
Fifty-Year Incidence of WaldenstrAPm Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. ( 29656787 )
2018
4
Waldenstrom's Macroglobulinemia: An Update. ( 29326801 )
2018
5
Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory WaldenstrAPm macroglobulinemia: evidence for a graft-<i>versus</i>-lymphoma effect. ( 29545343 )
2018
6
[<sup>18</sup>F]Florbetaben PET-CT confirms AL amyloidosis in a patient with WaldenstrAPm's Macroglobulinemia. ( 29650640 )
2018
7
Chronic diarrhea: A case of WaldenstrAPm Macroglobulinemia. ( 29463427 )
2018
8
Fitting mSMART Into the Current Clinical Management of WaldenstrAPm Macroglobulinemia. ( 29392274 )
2018
9
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With WaldenstrAPm Macroglobulinemia. ( 29685422 )
2018
10
MYD88 mutation status does not impact overall survival in WaldenstrAPm macroglobulinemia. ( 29080258 )
2018
11
A rare neurological complication of Waldenstrom's Macroglobulinemia. ( 29113857 )
2018
12
Cardiopulmonary Bypass in the Setting of WaldenstrAPm's Macroglobulinemia. ( 29921992 )
2018
13
Ibrutinib withdrawal symptoms in patients with WaldenstrAPm macroglobulinemia. ( 29472352 )
2018
14
WaldenstrAPm macroglobulinemia treatment algorithm 2018. ( 29712895 )
2018
15
Waldenstrom macroglobulinemia involving the superior rectus muscle. ( 29780960 )
2018
16
Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of WaldenstrAPm's macroglobulinemia? ( 29922935 )
2018
17
A safety profile of medications used to treat WaldenstrAPm's macroglobulinemia. ( 29768934 )
2018
18
Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for WaldenstrAPm Macroglobulinemia. ( 29439186 )
2018
19
Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With WaldenstrAPm Macroglobulinemia. ( 29742593 )
2018
20
Impact of ibrutinib dose intensity on patient outcomes in previously treated WaldenstrAPm macroglobulinemia. ( 29773590 )
2018
21
Kidney Involvement of Patients with WaldenstrAPm Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. ( 29848505 )
2018
22
Calorimetric markers for monitoring of multiple myeloma and WaldenstrAPm's macroglobulinemia patients. ( 29362827 )
2018
23
WaldenstrAPm macroglobulinemia presenting as cryoglobulinemic type II membranoproliferative glomerulonephritis. ( 29571917 )
2018
24
Duodenal Scalloping Diagnoses WaldenstrAPm Macroglobulinemia. ( 29660526 )
2018
25
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. ( 28583038 )
2018
26
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in WaldenstrAPm Macroglobulinemia. ( 29661775 )
2018
27
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. ( 29218718 )
2018
28
Lung consolidation as a rare presentation of lymphoplasmacytic lymphoma with extramedullary WaldenstrAPm's macroglobulinemia. ( 29686791 )
2018
29
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic WaldenstrAPm Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. ( 29963517 )
2018
30
Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with WaldenstrAPm Macroglobulinemia. ( 29756293 )
2018
31
Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in WaldenstrAPm macroglobulinemia. ( 29567768 )
2018
32
True, true unrelated? Coexistence of Waldenstrom's macroglobulinemia and cardiac transthyretin Amyloidosis. ( 29674499 )
2018
33
Intensely Pruritic Papules and Plaques in Waldenstrom's Macroglobulinemia. ( 29386839 )
2018
34
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrAPm macroglobulinemia. ( 29610969 )
2018
35
Phase 3 Trial of Ibrutinib plus Rituximab in WaldenstrAPm's Macroglobulinemia. ( 29856685 )
2018
36
Fitting mSMART Into the Current Clinical Management of WaldenstrAPm Macroglobulinemia-Reply. ( 29392293 )
2018
37
Current options to manage WaldenstrAPm's macroglobulinemia. ( 28592170 )
2017
38
Dexamethasone, rituximab and cyclophosphamide for relapsedA and/or refractory and treatment-naA^ve patients with Waldenstrom macroglobulinemia. ( 28786474 )
2017
39
Normothermic Cardiopulmonary Bypass in Patient With WaldenstrAPm's Macroglobulinemia and Cryoglobulinemia: A Case Report. ( 28520564 )
2017
40
Diagnosis and Management of WaldenstrAPm Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. ( 28056114 )
2017
41
Retrospective analysis of prognostic factors for WaldenstrOsm macroglobulinemia: a multicenter cooperative study in Japan. ( 28687991 )
2017
42
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. ( 28754818 )
2017
43
Cutaneous Infiltration due to WaldenstrAPm Macroglobulinemia. ( 28784233 )
2017
44
The importance of the genomic landscape in WaldenstrAPm's Macroglobulinemia for targeted therapeutical interventions. ( 28423722 )
2017
45
What should be the goal of therapy for WaldenstrAPm macroglobulinemia patients? Complete response should be the goal of therapy. ( 29296899 )
2017
46
New developments in the management of WaldenstrAPm macroglobulinemia. ( 28331368 )
2017
47
Toward personalized treatment in WaldenstrAPm macroglobulinemia. ( 29222280 )
2017
48
WaldenstrAPm Macroglobulinemia: Review of Pathogenesis and Management. ( 28366781 )
2017
49
Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. ( 28043164 )
2017
50
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia. ( 29203585 )
2017

Variations for Macroglobulinemia

Expression for Macroglobulinemia

Search GEO for disease gene expression data for Macroglobulinemia.

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 AKT1 BTK CD27 CD40LG CD70 IL6
2
Show member pathways
13.64 AKT1 BTK CD27 CD40LG CD70 CXCL12
3
Show member pathways
13.5 AKT1 BTK CD27 CD40LG CD70 CXCL12
4
Show member pathways
13.39 AKT1 BTK CXCL12 CXCR4 IL6 ITGAE
5
Show member pathways
13.22 AKT1 CD27 CD40LG CD70 IL6 MYD88
6
Show member pathways
12.93 AKT1 BTK CXCL12 IL6 ITGAE
7
Show member pathways
12.74 CD40LG CXCL12 CXCR4 IL6 TNFRSF13B TNFSF13B
8
Show member pathways
12.73 AKT1 BTK CXCR4 IL6
9
Show member pathways
12.72 AKT1 BTK CD27 CD40LG CD70 CXCL12
10
Show member pathways
12.59 AKT1 CD40LG CXCL12 IL6 MYD88 TNFSF13B
11
Show member pathways
12.57 AKT1 BTK CD27 CD40LG CD70 CXCL12
12
Show member pathways
12.55 AKT1 BTK CD27 CD40LG CD70 CXCL12
13
Show member pathways
12.54 AKT1 CD27 CD40LG CD70 CXCR4
14
Show member pathways
12.41 AKT1 CD40LG MYD88 TNFRSF13B TNFSF13B
15 12.38 BTK CD40LG CXCL12 CXCR4 MYD88 PAX5
16
Show member pathways
12.12 AKT1 BTK IL6 MYD88
17
Show member pathways
11.99 AKT1 BTK CXCL12 IL6 TNFSF13B
18 11.81 AKT1 CXCL12 CXCR4 IL6
19 11.76 CXCL12 IL6 TNFSF13B
20 11.74 BTK CD40LG CXCL12 MYD88 TNFSF13B
21 11.68 AKT1 CXCL12 CXCR4
22
Show member pathways
11.66 CD40LG TNFRSF13B TNFSF13B
23 11.61 AKT1 CXCL12 CXCR4
24 11.54 CD27 CD40LG CD70
25 11.46 CD40LG IL6 MYD88
26 11.44 AKT1 BTK IL6
27 11.38 CD27 CD40LG CXCR4 PAX5 TNFRSF13B
28 11.3 BTK CD40LG TNFRSF13B
29 11.2 CXCL12 CXCR4 TNFRSF13B
30 11.18 CD27 CD70 TNFRSF13B TNFSF13B

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.4 AKT1 BTK CD27 CD40LG CD70 CXCL12
2 external side of plasma membrane GO:0009897 9.26 CD27 CD40LG CXCL12 ITGAE

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.93 AKT1 BTK CD27 CXCR4 MYD88
2 negative regulation of apoptotic process GO:0043066 9.89 AKT1 CD27 CD40LG IL6 MYD88
3 regulation of signaling receptor activity GO:0010469 9.77 CD40LG CD70 CXCL12 IL6 TNFSF13B
4 platelet activation GO:0030168 9.73 AKT1 CD40LG IL6
5 response to virus GO:0009615 9.72 CXCL12 CXCR4 MYD88
6 T cell costimulation GO:0031295 9.65 AKT1 CD40LG TNFSF13B
7 immune response GO:0006955 9.63 CD27 CD40LG CD70 CXCL12 IL6 TNFSF13B
8 positive regulation of T cell proliferation GO:0042102 9.61 CD40LG IL6 TNFSF13B
9 endocrine pancreas development GO:0031018 9.58 AKT1 IL6
10 B cell homeostasis GO:0001782 9.58 TNFRSF13B TNFSF13B
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.58 AKT1 IL6 MYD88
12 negative regulation of B cell proliferation GO:0030889 9.57 BTK TNFRSF13B
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.56 BTK CD40LG IL6 MYD88
14 positive regulation of B cell differentiation GO:0045579 9.52 BTK CD27
15 immunoglobulin mediated immune response GO:0016064 9.51 CD27 MYD88
16 response to peptidoglycan GO:0032494 9.46 IL6 MYD88
17 inflammatory response GO:0006954 9.43 AKT1 CD27 CD40LG CXCR4 IL6 MYD88
18 immunoglobulin secretion GO:0048305 9.32 CD40LG TNFSF13B
19 tumor necrosis factor-mediated signaling pathway GO:0033209 9.02 CD27 CD40LG CD70 TNFRSF13B TNFSF13B

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 BTK CD70 CXCL12 MYD88 TNFSF13B
2 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG CD70 TNFSF13B
3 cytokine activity GO:0005125 9.02 CD40LG CD70 CXCL12 IL6 TNFSF13B

Sources for Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....